Zydus Launches Semaglutide Injection in an Innovative & Reusable Multi-dose Pen Device in India

News Desk, News Nation 360 : Following the patent expiration in India, Zydus Lifesciences Limited, a global lifesciences firm driven by innovation, introduced Semaglutide Injection under the brand names SEMAGLYNTM, MASHEMATM, and ALTERMETM. The production and distribution of Semaglutide injection for the treatment of Type 2 Diabetes Mellitus and obesity indications had already received permission from the Drug Controller General of India (DCGI). Zydus provides a revolutionary reusable multi-dose pen device, in contrast to existing treatment choices that frequently need patients to buy many single-dose pens as they gradually titrate their dosage. This development will improve adherence, increase convenience, and drastically reduce the total cost of therapy by allowing patients and physicians to easily choose and administer several dose strengths from a single pen. The 15 mg/3 ml cartridge of Zydus' semaglutide injectable would be produced at Zydus Biotech Park in Ahmedabad. The treatment will cost about Rs. 2,200 per month on average. Obesity and diabetes are two of the biggest health issues facing India today. 2 GLP-1-based therapies may be crucial in resolving this expanding public health issue. The International Diabetes Federation estimates that 8.9 crore adults in India, or 10.5% of the adult population, have diabetes. At the same time, obesity is quickly increasing in all age categories. The prevalence of obesity among adults has risen by 91% in women (from 12.6% to 24.0%) and 146% in men (from 9.3% to 22.9%). These patterns indicate that the nation's health situation is becoming worse.

Pic - Courtesy